Expanding the Armory: Predicting and Tuning Covalent Warhead Reactivity
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Targeted covalent inhibition is an established approach for increasing the potency and selectivity of potential drug candidates, as well as identifying potent and selective tool compounds for target validation studies. It is evident that identification of reversible recognition elements is essential for selective covalent inhibition, but this must also be achieved with the appropriate level of inherent reactivity of the reactive functionality (or “warhead”). Structural changes that increase or decrease warhead reactivity, guided by methods to predict the effect of those changes, have the potential to tune warhead reactivity and negate issues related to potency and/or toxicity. The half-life to adduct formation with glutathione (GSH t 1/2 ) is a useful assay for measuring the reactivity of cysteine-targeting covalent warheads but is limited to synthesized molecules. In this manuscript we assess the ability of several experimental and computational approaches to predict GSH t 1/2 for a range of cysteine targeting warheads, including a novel method based on p K a . Furthermore, matched molecular pairs analysis has been performed against our internal compound collection, revealing structure–activity relationships between a selection of different covalent warheads. These observations and methods of prediction will be valuable in the design of new covalent inhibitors with desired levels of reactivity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In some cases, covalent inhibitors can be designed to be cleared rapidly after blocking the PPI, which could reduce non-mechanism-based toxicity [37, 139].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [139]
Citations
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Bochevarov, A. D., Harder, E., Hughes, T. F., Greenwood, J. R., Braden, D. A., Philipp, D. M., Rinaldo, D., Halls, M. D., Zhang, J., & Friesner, R. A. (2013) · International Journal of Quantum Chemistry · doi:10.1002/qua.24481 · Cited by 1,798
Cysteine Proteases and Their Inhibitors
Otto, H.-H., & Schirmeister, T. (1997) · Chemical Reviews · doi:10.1021/cr950025u · Cited by 759
Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state
Patricelli, M. P., Janes, M. R., Li, L.-S., Hansen, R., Peters, U., Kessler, L. V., Chen, Y., Kucharski, J. M., Feng, J., Ely, T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1105 · Cited by 759
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691
Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
Liu, Q., Sabnis, Y., Zhao, Z., Zhang, T., Buhrlage, S. J., Jones, L. H., & Gray, N. S. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.12.006 · Cited by 652
Jackson, P. A., Widen, J. C., Harki, D. A., & Brummond, K. M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00788 · Cited by 588
Targeted Covalent Inhibitors for Drug Design
Baillie, T. A. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201601091 · Cited by 578
Bauer, R. A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.05.005 · Cited by 534
Research works printed but not linked: 5
- 2017, Schrödinger Release 2017-2
- 2017, Schrödinger Release 2017-2: Ligprep
- Frisch M. J., 2009, Gaussian 09, Revision E.09
- 2017, Schrödinger Release 2017-2: Macromodel
- 2017, Jaguar, Version 9.5
Cited by
Gehringer, M., & Laufer, S. A. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01153 · Cited by 714
Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles
Eaton, J. K., Furst, L., Ruberto, R. A., Moosmayer, D., Hilpmann, A., Ryan, M. J., Zimmermann, K., Cai, L. L., Niehues, M., Badock, V., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0501-5 · Cited by 489
Structure-based design of targeted covalent inhibitors
Lonsdale, R., & Ward, R. A. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00220c · Cited by 344
Self-citationAdvances in covalent kinase inhibitors
Abdeldayem, A., Raouf, Y. S., Constantinescu, S. N., Moriggl, R., & Gunning, P. T. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00720b · Cited by 317
Next generation 3D pharmacophore modeling
Schaller, D., Šribar, D., Noonan, T., Deng, L., Nguyen, T. N., Pach, S., Machalz, D., Bermudez, M., & Wolber, G. (2020) · WIREs Computational Molecular Science · doi:10.1002/wcms.1468 · Cited by 269
Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update
Hillebrand, L., Liang, X. J., Serafim, R. A. M., & Gehringer, M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01825 · Cited by 199
Fragment‐based drug discovery—the importance of high‐quality molecule libraries
Bon, M., Bilsland, A. E., Bower, J. F., & McAulay, K. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13277 · Cited by 175
Comparative Evaluation of Covalent Docking Tools
Scarpino, A., Ferenczy, G. G., & Keserű, G. M. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00228 · Cited by 153
A road map for prioritizing warheads for cysteine targeting covalent inhibitors
Ábrányi‐Balogh, P., Petri, L., Imre, T., Szijj, P. A., Scarpino, A., Hrast, M., Mitrović, A., Fonović, U. P., Németh, K., Barreteau, H., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.010 · Cited by 140
Characterising covalent warhead reactivity
Martin, J. S., MacKenzie, C. J., Fletcher, D., & Gilbert, I. H. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.04.002 · Cited by 125
“Synthesis of N-phenylethenesulfonamide (15) Aniline (100mg, 1.074mmol, 1 equ) and 2-chloroethanesulfonyl chloride (175mg, 1.074mmol, 1 equ) were dissolved in DCM (10ml) and cooled to 0 °C. Triethylamine (326mg, 3.22mmol, 3 equ) was added and the reaction was stirred for 10min then allowed to warm up to room temperatur…”
BackgroundMethodInfluentialMons, E., Roet, S., Kim, R. Q., & Mulder, M. P. C. (2022) · Current Protocols · doi:10.1002/cpz1.419 · Cited by 138
“…with a high kinact/KI value for the desired enzyme target (Mah, Thomas, & Shafer, 2014; Schwartz et al., 2014), while minimizing the intrinsic reactivity with undesired enzymes such as GSH (Guan, Williams, Pan, & Liu, 2021; Lonsdale et al., 2017; Martin, MacKenzie, Fletcher, & Gilbert, 2019).”
BackgroundMons, E., Jansen, I. D. C., Loboda, J., van Doodewaerd, B. R., Hermans, J., Verdoes, M., van Boeckel, C. A. A., van Veelen, P. A., Turk, B., Turk, D., et al. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b11027 · Cited by 112
Schießer, S., Chepliaka, H., Kollback, J., Quennesson, T., Czechtizky, W., & Cox, R. J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01457 · Cited by 114
Covalent fragment libraries in drug discovery
Keeley, A. B., Petri, L., Ábrányi‐Balogh, P., & Keserű, G. M. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.03.016 · Cited by 118
Macip, G., Garcia‐Segura, P., Mestres‐Truyol, J., Saldivar‐Espinoza, B., Ojeda, M. J., Gimeno, A., Cereto‐Massagué, A., García-Vallvé, S., & Pujadas, G. (2021) · Medicinal Research Reviews · doi:10.1002/med.21862 · Cited by 115
“recognized by the target binding site to place a reactive functional group, usually referred to as a warhead, in an appropriate position to form a covalent bond between the inhibitor and its target.(21,81) The formation of the covalent bond depends not only on the correct structural complementarity between the protein…”
BackgroundCovalent Small Molecules as Enabling Platforms for Drug Discovery
Dalton, S. E., & Campos, S. (2020) · ChemBioChem · doi:10.1002/cbic.201900674 · Cited by 104
The design and development of covalent protein-protein interaction inhibitors for cancer treatment
Cheng, S.-S., Yang, G.-J., Wang, W., Leung, C.-H., & Ma, D.-L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00850-0 · Cited by 98
“In some cases, covalent inhibitors can be designed to be cleared rapidly after blocking the PPI, which could reduce non-mechanismbased toxicity [37, 139].”
BackgroundBeyond cysteine: recent developments in the area of targeted covalent inhibition
Mukherjee, H., & Grimster, N. P. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.05.011 · Cited by 95
Electrophilic warheads in covalent drug discovery: an overview
Péczka, N., Orgován, Z., Ábrányi‐Balogh, P., & Keserű, G. M. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2034783 · Cited by 93
“These usually consist of the ligand and a surrogate molecule for the targeted sidechain in implicit or explicit solvent [63].”
BackgroundCan Cysteine Protease Cross-Class Inhibitors Achieve Selectivity?
Cianni, L., Feldmann, C., Gilberg, E., Gütschow, M., Juliano, L., Leitão, A., Bajorath, J., & Montanari, C. A. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00683 · Cited by 94
Zaidman, D., Gehrtz, P., Filep, M., Fearon, D., Gabizon, R., Douangamath, A., Prilusky, J., Duberstein, S., Cohen, G., Owen, C. D., et al. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.05.018 · Cited by 88
“, 2019), which remain challenging to predict computationally (Lonsdale et al., 2017; Palazzesi et al., 2019, 2020) and thus require careful evaluation.”
BackgroundBröker, J., Waterson, A. G., Smethurst, C., Kessler, D., Böttcher, J., Mayer, M., Gmaschitz, G., Phan, J., Little, A., Abbott, J. R., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01120 · Cited by 96
McAulay, K., Hoyt, E. A., Thomas, M. C., Schimpl, M., Bodnarchuk, M. S., Lewis, H. J., Barratt, D. G., Bhavsar, D., Robinson, D. M., Deery, M. J., et al. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b13391 · Cited by 91
Self-citationNucleophilicity of Glutathione: A Link to Michael Acceptor Reactivities
Mayer, R. J., & Ofial, A. R. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201909803 · Cited by 86
CovalentInDB: a comprehensive database facilitating the discovery of covalent inhibitors
Du, H., Gao, J., Weng, G., Ding, J., Chai, X., Pang, J., Kang, Y., Li, D., Cao, D., & Hou, T. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa876 · Cited by 80
“Moreover, some computational algorithms for covalent drug design have been developed, such as covalent docking (13), binding free energy calculation (14,15), warhead reactivity prediction (16), covalent binding site prediction (17), etc.”
BackgroundBirkholz, A. B., Kopecky, D. J., Volak, L. P., Bartberger, M. D., Chen, Y., Tegley, C. M., Arvedson, T., McCarter, J. D., Fotsch, C. H., & Cee, V. J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00749 · Cited by 78
The expanding repertoire of covalent warheads for drug discovery
Mehta, N. V., & Degani, M. S. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103799 · Cited by 86
Development of covalent inhibitors: Principle, design, and application in cancer
Zheng, L., Li, Y., Wu, D., Xiao, H., Zheng, S., Wang, G., & Sun, Q. (2023) · MedComm – Oncology · doi:10.1002/mog2.56 · Cited by 71
Șandor, A., Ionuţ, I. A., Marc, G., Oniga, I., Eniu, D. T., & Oniga, O. (2023) · Pharmaceuticals · doi:10.3390/ph16040534 · Cited by 91
Quantum chemical package Jaguar: A survey of recent developments and unique features
Cao, Y., Balduf, T., Beachy, M. D., Bennett, M. C., Bochevarov, A. D., Chien, A. D., Dub, P. A., Dyall, K. G., Furness, J. W., Halls, M. D., et al. (2024) · The Journal of Chemical Physics · doi:10.1063/5.0213317 · Cited by 82
Covalent Docking Identifies a Potent and Selective MKK7 Inhibitor
Shraga, A., Olshvang, E., Davidzohn, N., Khoshkenar, P., Germain, N., Shurrush, K., Carvalho, S., Avram, L., Albeck, S., Unger, T., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.10.011 · Cited by 64
Covalent Proximity Scanning of a Distal Cysteine to Target PI3Kα
Borsari, C., Keleş, E., McPhail, J. A., Schäfer, A., Sriramaratnam, R., Goch, W., Schaefer, T., Pascale, M. D., Bal, W., Gstaiger, M., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c13568 · Cited by 70
“Up-to-date, several approaches have been applied to predict warhead reactivity, including NMR chemical shifts, 49 p K a assessments, 50 and quantum mechanics/molecular mechanics (QM/MM).”
Cregg, J., Pota, K., Tomlinson, A. C. A., Yano, J. K., Marquez, A., Liu, Y., Schulze, C. J., Seamon, K. J., Holderfield, M. T., Wei, X., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02313 · Cited by 80
Targeting Ras-, Rho-, and Rab-family GTPases via a conserved cryptic pocket
Morstein, J., Bowcut, V., Fernando, M. C., Yang, Y., Zhu, L., Jenkins, M. L., Evans, J. T., Guiley, K. Z., Peacock, D. M., Krahnke, S., et al. (2024) · Cell · doi:10.1016/j.cell.2024.08.017 · Cited by 70
Voice, A. T., Tresadern, G., Twidale, R. M., van Vlijmen, H., & Mulholland, A. J. (2021) · Chemical Science · doi:10.1039/d0sc06122k · Cited by 58
Oyedele, A.-Q. K., Ogunlana, A. T., Boyenle, I. D., Adeyemi, A. O., Temionu, O. R., Adelusi, T. I., Abdul-Hammed, M., Elegbeleye, O. E., & Odunitan, T. T. (2022) · Molecular Diversity · doi:10.1007/s11030-022-10523-4 · Cited by 59
“It should be highlighted, however that the mere presence of a reactive residue near a ligand-binding site does not necessarily justify a covalent method; the target residue's local chemical environment must be carefully assessed to establish its suitability [36, 37].”
BackgroundRanking Reversible Covalent Drugs: From Free Energy Perturbation to Fragment Docking
Zhang, H., Jiang, W., Chatterjee, P., & Luo, Y. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00959 · Cited by 57
Reactivity of Covalent Fragments and Their Role in Fragment Based Drug Discovery
McAulay, K., Bilsland, A. E., & Bon, M. (2022) · Pharmaceuticals · doi:10.3390/ph15111366 · Cited by 60
“A library which includes fragments with a range of reactivities [79] and electrophilic groups [61] is therefore beneficial since there is no ‘one size fits all’ warhead.”
BackgroundQuantum Chemical Methods for Modeling Covalent Modification of Biological Thiols
Awoonor‐Williams, E., Isley, W. C., Dale, S. G., Johnson, E. R., Yu, H. B., Becke, A. D., Roux, B., & Rowley, C. N. (2019) · Journal of Computational Chemistry · doi:10.1002/jcc.26064 · Cited by 49
Petri, L., Egyed, A., Bajusz, D., Imre, T., Hetényi, A., Martinek, T. A., Ábrányi‐Balogh, P., & Keserű, G. M. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112836 · Cited by 53
BIreactive: A Machine-Learning Model to Estimate Covalent Warhead Reactivity
Palazzesi, F., Hermann, M. R., Grundl, M. A., Pautsch, A., Seeliger, D., Tautermann, C. S., & Weber, A. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b01058 · Cited by 49
The role of quantum chemistry in covalent inhibitor design
Mihalovits, L. M., Ferenczy, G. G., & Keserű, G. M. (2021) · International Journal of Quantum Chemistry · doi:10.1002/qua.26768 · Cited by 48
Affinity and Selectivity Assessment of Covalent Inhibitors by Free Energy Calculations
Mihalovits, L. M., Ferenczy, G. G., & Keserű, G. M. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00834 · Cited by 47
A Fast Ab Initio Predictor Tool for Covalent Reactivity Estimation of Acrylamides
Palazzesi, F., Grundl, M. A., Pautsch, A., Weber, A., & Tautermann, C. S. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00316 · Cited by 42
Bianco, G., Goodsell, D. S., & Forli, S. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.10.005 · Cited by 44
“Lonsdale [31] presents a novel approach using pK a assessment, which is compared with previously reported approaches such as NMR chemical shifts and quantum mechanical (QM) model calculations, to estimate reactivity of a series of acrylamides using glutathione.”
MethodReversible Covalent Inhibition─Desired Covalent Adduct Formation by Mass Action
Patel, D., Huma, Z. E., & Duncan, D. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.3c00805 · Cited by 50
Systematic Studies on the Protocol and Criteria for Selecting a Covalent Docking Tool
Wen, C., Yan, X., Gu, Q., Du, J., Wu, D., Lu, Y., Zhou, H., & Xu, J. (2019) · Molecules · doi:10.3390/molecules24112183 · Cited by 40
Current and Future Challenges in Modern Drug Discovery
Tautermann, C. S. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0282-9_1 · Cited by 50
Covalent chemical probes for protein kinases
Serafim, R. A. M., Haarer, L., Pedreira, J. G. B., & Gehringer, M. (2023) · Current Research in Chemical Biology · doi:10.1016/j.crchbi.2022.100040 · Cited by 35
Covalent Proteomimetic Inhibitor of the Bacterial FtsQB Divisome Complex
Paulussen, F. M., Schouten, G. K., Moertl, C., Verheul, J., Hoekstra, I., Koningstein, G. M., Hutchins, G. H., Alkir, A., Luirink, R. A., Geerke, D. P., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c06304 · Cited by 32
Yamane, D., Tetsukawa, R., Zenmyo, N., Tabata, K., Yoshida, Y., Matsunaga, N., Shindo, N., & Ojida, A. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00737 · Cited by 35
WIDOCK: a reactive docking protocol for virtual screening of covalent inhibitors
Scarpino, A., Petri, L., Knez, D., Imre, T., Ábrányi‐Balogh, P., Ferenczy, G. G., Gobec, S., & Keserű, G. M. (2021) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-020-00371-5 · Cited by 36
“We optimized the transition state and product geometries (in the case of Michael acceptors we always considered the s-cis transitional geometry [68]) with the 6-311G+(d,p) basis set.”
MethodMihalovits, L. M., Ferenczy, G. G., & Keserű, G. M. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00691 · Cited by 31
Bonatto, V., Shamim, A., Rocho, F. D. R., Leitão, A., Luque, F. J., Lameira, J., & Montanari, C. A. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00515 · Cited by 32
Covalent hits and where to find them
Lucas, S. C. C., Blackwell, J. H., Hewitt, S. H., Semple, H., Whitehurst, B. C., & Xu, H. (2024) · SLAS DISCOVERY · doi:10.1016/j.slasd.2024.01.003 · Cited by 31
“This was demonstrated by Lonsdale et al. during their work on CRG reactivity [32].”
MethodStructure–Reactivity Studies of 2-Sulfonylpyrimidines Allow Selective Protein Arylation
Pichon, M. M., Drelinkiewicz, D., Lozano, D., Moraru, R., Hayward, L. J., Jones, M., McCoy, M. A., Allstrum-Graves, S., Balourdas, D.-I., Joerger, A. C., et al. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00322 · Cited by 29
Proj, M., Knez, D., Sosič, I., & Gobec, S. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.03.008 · Cited by 32
Conole, D., Cao, F., Ende, C. W. A., Xue, L., Kantesaria, S., Kang, D., Jin, J. H., Owen, D. R., Lohr, L., Schenone, M., et al. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202311190 · Cited by 26
Assessment of Tractable Cysteines for Covalent Targeting by Screening Covalent Fragments
Petri, L., Ábrányi‐Balogh, P., Imre, T., Pálfy, G., Perczel, A., Knez, D., Hrast, M., Gobec, M., Sosič, I., Nyíri, K., et al. (2020) · ChemBioChem · doi:10.1002/cbic.202000700 · Cited by 27
Nucleophilic Reactivities of Thiophenolates
Jüstel, P. M., Pignot, C. D., & Ofial, A. R. (2021) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.1c00025 · Cited by 23
Meden, A., Knez, D., Brazzolotto, X., Modeste, F., Perdih, A., Pišlar, A. H., Zorman, M., Zorović, M., Denic, M., Pajk, S., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115048 · Cited by 25
Technologies for Direct Detection of Covalent Protein–Drug Adducts
Mons, E., Kim, R. Q., & Mulder, M. P. C. (2023) · Pharmaceuticals · doi:10.3390/ph16040547 · Cited by 26
“A warhead should have the right balance between intrinsic chemical reactivity and selectivity, quickly forming a covalent adduct with the desired target but not (or much slower) with undesired cellular components [26,27].”
BackgroundDUckCov: a Dynamic Undocking‐Based Virtual Screening Protocol for Covalent Binders
Rachman, M. M., Scarpino, A., Bajusz, D., Pálfy, G., Vida, I., Perczel, A., Barril, X., & Keserű, G. M. (2019) · ChemMedChem · doi:10.1002/cmdc.201900078 · Cited by 23
Covalent-Allosteric Inhibitors: Do We Get the Best of Both Worlds?
Tao, H., Yang, B., Farhangian, A., Xu, K., Li, T., Zhang, Z., & Li, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02760 · Cited by 22
Systematic Exploration of Privileged Warheads for Covalent Kinase Drug Discovery
Zhao, Z., & Bourne, P. E. (2022) · Pharmaceuticals · doi:10.3390/ph15111322 · Cited by 19
Himmelbauer, M. K., Bajrami, B., Basile, R., Capacci, A. G., Chen, T., Choi, C. K., Gilfillan, R., de Turiso, F. G.-L., Gu, C., Hoemberger, M., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00220 · Cited by 22
“It is worth mentioning that a thorough warhead screen 58,59 to replace the acrylamide moiety in compound 21 with an alternative electrophile that maintained high activity for Cys481 and reduced promiscuity over other nucleophiles, such as glutathione, was performed at this stage.”
Wen, W., Cao, H., Xu, Y., Ren, Y., Rao, L., Shao, X., Chen, H., Wu, L., Liu, J., Chen, S., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00336 · Cited by 20
Mechanism-Based and Computational-Driven Covalent Drug Design
Luo, Y. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c01278 · Cited by 23
Recent advances in the design of small molecular drugs with acrylamides covalent warheads
Liang, L., Zhang, Z., You, Q., & Guo, X. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117902 · Cited by 23
Limitations of Ligand-Only Approaches for Predicting the Reactivity of Covalent Inhibitors
Voice, A. T., Tresadern, G., van Vlijmen, H., & Mulholland, A. J. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00404 · Cited by 18
Development of Benzenesulfonamide Derivatives as Potent Glutathione Transferase Omega-1 Inhibitors
Xie, Y., Tummala, P., Oakley, A. J., Deora, G. S., Nakano, Y., Rooke, M., Cuellar, M. E., Strasser, J. M., Dahlin, J. L., Walters, M. A., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01391 · Cited by 21
Slow-Binding and Covalent HDAC Inhibition: A New Paradigm?
Raouf, Y. S., & Moreno–Yruela, C. (2024) · JACS Au · doi:10.1021/jacsau.4c00828 · Cited by 21
Chemical Reactivity Prediction: Current Methods and Different Application Areas
Ertl, P., Gerebtzoff, G., Lewis, R. A., Münkler, H., Schneider, N., Sirockin, F., Stiefl, N., & Tosco, P. (2021) · Molecular Informatics · doi:10.1002/minf.202100277 · Cited by 19
CovaDOTS: In Silico Chemistry-Driven Tool to Design Covalent Inhibitors Using a Linking Strategy
Hoffer, L., Sáez‐Ayala, M., Horvath, D., Varnek, A. A., Morelli, X., & Roche, P. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00960 · Cited by 19
Srinivasan, B. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02863 · Cited by 20
Lu, H., Sun, D., Wang, Z., Cui, H., Min, L., Zhang, H., Zhang, Y., Wu, J., Cai, X., Ding, X., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01616 · Cited by 17
Huang, S., Kim, K.-M., Musgrave, G. M., Sharp, M., Sinha, J., Stansbury, J. W., Musgrave, C. B., & Bowman, C. N. (2021) · Polymer Chemistry · doi:10.1039/d1py00363a · Cited by 19
dos Santos, A. M., Oliveira, A. R. S., da Costa, C. H. S., Kenny, P. W., Montanari, C. A., Júnior, J. D. J. G. V., & Lameira, J. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00466 · Cited by 18
Castelli, R., Bozza, N., Cavazzoni, A., Bonelli, M. A., Vacondio, F., Ferlenghi, F., Callegari, D., Silva, C., Rivara, S., Lodola, A., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.029 · Cited by 17
Comparative reactivity profiling of cysteine-specific probes by chemoproteomics
Yang, F., Chen, N., Wang, F., Jia, G., & Wang, C. (2022) · Current Research in Chemical Biology · doi:10.1016/j.crchbi.2022.100024 · Cited by 16
Hasan, M. N., Ray, M., & Saha, A. (2023) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.3c04710 · Cited by 17
Targeting Cytotoxic Agents through EGFR-Mediated Covalent Binding and Release
Morese, P. A., Anthony, N. G., Bodnarchuk, M. S., Jennings, C., Martin, M. P., Noble, R. A., Phillips, N., Thomas, H. D., Wang, L.-Z., Lister, A. S., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00845 · Cited by 14
Self-citationLucas, S. C. C., Milbradt, A. G., Blackwell, J. H., Bonomo, S., Brierley, A., Cassar, D. J., Freeman, J., Hadfield, T. E., Morrill, L. A., Riemens, R., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00781 · Cited by 15
Liu, R., Vázquez-Montelongo, E. A., Ma, S., & Shen, J. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00720 · Cited by 15
Reformulating Reactivity Design for Data-Efficient Machine Learning
Lewis‐Atwell, T., Beechey, D., Şimşek, Ö., & Grayson, M. N. (2023) · ACS Catalysis · doi:10.1021/acscatal.3c02513 · Cited by 13
Discovery and Structural Optimization of Covalent ZAP-70 Kinase Inhibitors against Psoriasis
Rao, D., Yang, T., Feng, H., An, Q., Zhang, S., Yu, J., Ren, X., Diao, X., Huang, H., Tang, W., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00606 · Cited by 12
Warheads for designing covalent inhibitors and chemical probes
Ábrányi‐Balogh, P., & Keserű, G. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821433-6.00007-6 · Cited by 19
Discovery of a potent and selective covalent threonine tyrosine kinase (TTK) inhibitor
Sun, Y., Chen, Z., Liu, G., Chen, X., Shi, Z., Feng, H., Yu, L., Li, G., Ding, K., Huang, H., et al. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.107053 · Cited by 12
Moraru, R., Valle‐Argos, B., Minton, A. R., Buermann, L. E., Pan, S., Wales, T. E., Joseph, R. E., Andreotti, A. H., Strefford, J. C., Packham, G. K., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01927 · Cited by 12
Targeting PfCLK3 with Covalent Inhibitors: A Novel Strategy for Malaria Treatment
Brettell, S. B., Janha, O., Begen, A., Cann, G., Sharma, S., Olaniyan, N., Yelland, T., Hole, A. J., Alam, B., Mayville, E., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01300 · Cited by 13
Synthesis and Target Identification of a Novel Electrophilic Warhead, 2-Chloromethylquinoline
Ni, F., Ekanayake, A. I., Espinosa, B., Yu, C., Sanders, J. N., Perino, J., Houk, K. N., & Zhang, C. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00359 · Cited by 10
On the intrinsic reactivity of highly potent trypanocidal cruzain inhibitors
Bonatto, V., Batista, P. H. J., Cianni, L., Vita, D. D., Silva, D. G., Cedron, R., Tezuka, D. Y., de Albuquerque, S., Moraes, C. B., Franco, C. H., et al. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00097c · Cited by 12
QM/MM and molecular dynamics investigation of the mechanism of covalent inhibition of TAK1 kinase
Toviwek, B., Gleeson, D., & Gleeson, M. P. (2021) · Organic & Biomolecular Chemistry · doi:10.1039/d0ob02273j · Cited by 11
Discovery of a potent, selective, and covalent ZAP-70 kinase inhibitor
Rao, D., Li, H., Ren, X., Sun, Y., Wen, C., Zheng, M., Huang, H., Tang, W., & Xu, S. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113393 · Cited by 11
Tillmanns, J., Häge, S., Borst, E. M., Wardin, J., Eickhoff, J., Klebl, B., Wagner, S., Wangen, C., Hahn, F., Socher, E., et al. (2023) · Cells · doi:10.3390/cells12081162 · Cited by 13
“In addition, further warheads (neratinib, osimeritinib and alantolactone), which likewise showed an antiviral effect but no NEC-binding activity, may act in an NEC-independent inhibitory manner, thus possibly binding to other virus-supportive targets, such as regulatory protein kinases [16,24,27,48].”
BackgroundBest Practices for Design and Characterization of Covalent Chemical Probes
Gabizon, R., Resnick, E., & London, N. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160745-00069 · Cited by 11
Luo, L., Zheng, T., Wang, Q., Liao, Y., Zheng, X., Zhong, A., Huang, Z., & Luo, H. (2022) · Pharmaceuticals · doi:10.3390/ph15050584 · Cited by 10
“Compared with the QSAR analysis under the traditional algorithm [34], the active structure–activity relationship model constructed by machine learning can better fit the data and can have better performance in terms of robustness and prediction accuracy [35].”
MethodFurther Considerations Towards an Effective and Efficient Oncology Drug Discovery DMPK Strategy
Williamson, B., Colclough, N., Fretland, A. J., Jones, B., Jones, R. D. O., & McGinnity, D. F. (2020) · Current Drug Metabolism · doi:10.2174/1389200221666200312104837 · Cited by 10
Self-citationHuang, F., Hu, H., Wang, K., Peng, C., Xu, W., Zhang, Y., Gao, J., Liu, Y., Zhou, H., Huang, R., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00372 · Cited by 11
Mihalovits, L. M., Ferenczy, G., & Keserű, G. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.08.008 · Cited by 5
“The optimization of these steps and thus the affinity and selectivity tuning of covalent inhibitors can be efficiently supported by computational methods [18,19].”
Metadata
- Authors
- Lonsdale, R., Burgess, J., Colclough, N., Davies, N. L., Lenz, E. M., Orton, A. L., & Ward, R. A.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Ward, Richard A.
- Venue
- Journal of Chemical Information and Modeling
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-11-21
- Volume
- 57
- Issue
- 12
- Pages
- 3124-3137
- ISSN
- 1549-9596 (ISSN-L)
- 1549-960X
- OpenAlex
- W2769901316
- Cited by
- 190
- References
- 28
- Citations by year
- 2026: 20 · 2025: 27 · 2024: 25 · 2023: 28 · 2022: 22 · 2021: 20 · 2020: 23 · 2019: 18 · 2018: 7
- FWCI
- 9.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Chemical Information and Modeling (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- covalent warheads, matched molecular pairs, structure-activity relationship, covalent inhibitors
- MeSH terms
- Acrylamides, Cysteine, Glutathione, Humans, Models, Molecular, Structure-Activity Relationship, Drug Discovery, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.